logo

For the Inventor, By the Inventor

Cambridge, United Kingdom

Crescendo Biologics Limited


USPTO Granted Patents = 21

% Expired Patents = 19.0


Trademarks = 3

Forward Citations = 131

Loading Chart...
Loading Chart...

33 inventors (with patents filed for the assignee):

goldMedal Yumin Teng (8 out of 9 patents)

silverMedal Brian Timothy McGuinness (8 out of 24 patents)

bronzeMedal Thomas Sandal (7 out of 7 patents)

4.  James Legg (5 out of 5 patents)

5.  Mike Romanos (5 out of 6 patents)

6.  Carolyn Edwards (4 out of 4 patents)

7.  Colette Johnston (4 out of 4 patents)

8.  Christine Rossant (4 out of 4 patents)

9.  Ulla Lashmar (4 out of 4 patents)

10.  Bryan Edwards (4 out of 4 patents)

11.  Nikki Royle (3 out of 3 patents)

12.  Martyna Lewandowska (3 out of 3 patents)

13.  Isabelle Osuch (3 out of 3 patents)

14.  Chris Rossant (3 out of 3 patents)

15.  Lorraine Thompson (3 out of 3 patents)


21 patents:

1. 12134643 - Compositions for treatment of disorders (2024-11-05),
2. 12077595 - Single domain antibodies that bind to CD137 (2024-09-03),
3. 11951172 - Therapeutic molecules that bind to LAG3 and PD1 (2024-04-09),
4. 11866510 - Chimeric antigen receptor with single domain antibody (2024-01-09),
5. 11814429 - Single domain antibodies to programmed cell death (PD-1) (2023-11-14),
6. 11746158 - Therapeutic molecules (2023-09-05),
7. 11667705 - IL-17A binding proteins (2023-06-06),
8. 11591398 - Single domain antibodies to programmed cell death protein 1 (PD-1) (2023-02-28),
9. 11401342 - Therapeutic molecules binding PSMA (2022-08-02),
10. 11312771 - Single-domain antibodies to programmed cell death 1 protein (PD-1), encoding nucleic acids and methods of using same (2022-04-26),
11. 11236174 - Therapeutic molecules (2022-02-01),
12. 10975161 - Molecules that bind prostate specific membrane antigen (PSMA) (2021-04-13),
13. 10947308 - Composition for treatment of disorders (2021-03-16),
14. 10654924 - IL-17A binding proteins (2020-05-19),
15. 10400030 - Methods for producing optimised therapeutic molecules (2019-09-03),
Company Overview
Crescendo Biologics Limited is a biotechnology company based in Cambridge, UK, specializing in the development of innovative therapeutic proteins. The company focuses on harnessing its proprietary Humabody technology platform to create next-generation biologics for the treatment of various diseases, including cancer and autoimmune disorders. By leveraging advanced protein engineering techniques, Crescendo aims to enhance the efficacy and safety of biologic therapies, positioning itself at the forefront of the biopharmaceutical industry.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

21 Patents

#51 in Cambridge

#849 in United Kingdom

#30,001 in the World

Cambridge, GB
Cambridge, United Kingdom

Crescendo Biologics Limited

Forward Citations = 131

33 inventors:

goldMedal Yumin Teng (8 out of 9 patents)

silverMedal Brian Timothy McGuinness (8 out of 24 patents)

bronzeMedal Thomas Sandal (7 out of 7 patents)

4.  James Legg (5 out of 5 patents)

5.  Mike Romanos (5 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Crescendo Biologics Limited. Retrieved from https://idiyas.com/company/crescendo-biologics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…